8-K: Glaukos Reports Record Q2 Sales, Raises Full-Year Guidance

Glaukos Corporation announced record second-quarter net sales of $95.7 million, a 19% increase year-over-year, and raised its full-year 2024 revenue guidance.

Summary

• Glaukos Corporation reported record net sales of $95.7 million for the second quarter of 2024, representing a 19% increase year-over-year on a reported basis and 20% on a constant currency basis.
• Glaucoma net sales reached a record $75.9 million, a 23% increase year-over-year, while Corneal Health net sales were $19.8 million, a 7% increase year-over-year.
• The company's gross margin was approximately 76%, with a non-GAAP gross margin of approximately 82%.
• Selling, general, and administrative expenses increased by 25% to $66.2 million, and research and development expenses increased by 4% to $34.4 million.
• The company reported a net loss of $53.9 million, or ($1.06) per diluted share, compared to a net loss of $32.8 million, or ($0.68) per diluted share, in the same period last year.
• Non-GAAP net loss was $26.3 million, or ($0.52) per diluted share, compared to a non-GAAP net loss of $26.6 million, or ($0.55) per diluted share, in the second quarter of 2023.
• Glaukos raised its 2024 net sales guidance to a range of $370 million to $376 million, up from the previous guidance of $357 million to $365 million.
• The company ended the quarter with approximately $266.4 million in cash, cash equivalents, short-term investments, and restricted cash.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record sales, increased guidance, and successful product launches. However, the net loss and increased expenses temper the overall optimism.

Positives

• The company achieved record net sales in the second quarter of 2024.
• Glaukos experienced strong growth in both its Glaucoma and Corneal Health franchises.
• The company successfully launched iDose TR and secured a permanent J-code for it.
• The new French CEPS agreement is expected to be a tailwind for the remainder of 2024.
• The company has a strong cash position of $266.4 million.
• Glaukos is progressing towards data readout for the second Phase 3 confirmatory trial for Epioxa.
• The company is preparing to commence a Phase 3 clinical trial for iDose TREX by the end of 2024.
• The exchange of convertible senior notes has de-leveraged and de-risked the balance sheet.

Negatives

• The company reported a net loss of $53.9 million for the second quarter of 2024.
• Selling, general, and administrative expenses increased by 25% year-over-year.
• The company experienced a decrease in cash and cash equivalents from $278.7 million in Q1 2024 to $266.4 million in Q2 2024.
• The U.S. Corneal Health franchise is experiencing headwinds due to the company's entry into the MDRP.
• The company is facing potential headwinds related to professional fee reimbursement for combination-cataract trabecular bypass surgery.

Risks

• The company's ability to successfully commercialize iDose TR is subject to uncertainties.
• General macroeconomic conditions, including foreign currency fluctuations, could impact the company's results.
• The company depends on a limited number of third-party suppliers, some of which are single-source.
• The company faces risks related to securing or maintaining adequate coverage or reimbursement by third-party payors.
• The company is subject to lengthy and expensive clinical trial processes and regulatory approval processes.
• There are risks of recalls or serious safety issues with the company's products.
• The company faces risks related to protecting its information systems against cyber threats and cybersecurity incidents.
• The company faces risks related to protecting its intellectual property against third parties and competitors.
• The company's ability to service its indebtedness is a risk.

Future Outlook

Glaukos expects full-year 2024 global consolidated net sales of $370 $376 million, taking into consideration potential contributions from iStent infinite and iDose TR, as well as potential headwinds in the U.S. Corneal Health franchise and combo-cataract MIGS competition.

Management Comments

• Our record second quarter results reflect successful global execution of our key strategic plans and growing momentum in our business, said Thomas Burns, Glaukos chairman and chief executive officer.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Industry Context

Glaukos's results reflect a growing trend in the ophthalmic industry towards minimally invasive surgical and pharmaceutical solutions for chronic eye diseases. The company's focus on dropless therapies and sustained-release technologies aligns with the industry's push for more patient-friendly and effective treatments.

Comparison to Industry Standards

• Glaukos's 20% constant currency revenue growth in Q2 2024 is strong compared to other medical device companies in the ophthalmic space, such as Alcon (ALC) and Johnson & Johnson Vision (JNJ), which typically see single-digit growth.
• The 82% non-GAAP gross margin is also high, indicating strong pricing power and efficient operations, compared to companies like STAAR Surgical (STAA) which have gross margins in the 70% range.
• The launch of iDose TR positions Glaukos as a leader in the emerging field of intracameral drug delivery, a space where companies like Allergan (now part of AbbVie) have also been investing.
• The company's R&D investment of over $600 million since 2018 demonstrates a commitment to innovation, which is crucial in the competitive medical device industry, similar to companies like Bausch Health (BHC) that invest heavily in new product development.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and strong sales growth.
• Employees may be motivated by the company's success and growth prospects.
• Customers (ophthalmic surgeons and patients) will benefit from the availability of new and innovative treatment options.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial health as improved due to the debt exchange.

Next Steps

• The company will host a conference call and webcast to discuss the results and provide additional information.
• Glaukos will continue to advance its pipeline of novel platforms.
• The company will continue to focus on expanding access for keratoconus patients.
• Glaukos will continue to advance commercial launch activities for iStent infinite and iDose TR.
• The company will continue to secure professional fee coverage and payment with MACs for iDose TR.
• Glaukos will progress towards data readout for the second Phase 3 confirmatory trial for Epioxa.
• The company will prepare to commence a Phase 3 clinical trial for iDose TREX by the end of 2024.

Key Dates

Keywords

Glaukos, glaucoma, corneal health, retinal disease, iStent, iDose TR, MIGS, ophthalmic, medical technology, pharmaceuticals, revenue, financial results